Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer

Appraisal Committee members

The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3‑year term. A list of the Committee members who took part in the discussions for this appraisal appears below. There are 4 Appraisal Committees, each with a chair and vice chair. Each Appraisal Committee meets once a month, except in December when there are no meetings. Each Committee considers its own list of technologies, and ongoing topics are not moved between Committees.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Dr Amanda Adler (Chair)
Consultant Physician, Addenbrooke's Hospital

Dr Ray Armstrong
Consultant Rheumatologist, Southampton General Hospital

Dr Jeff Aronson
Reader in Clinical Pharmacology, University Department of Primary Health Care, University of Oxford

Professor John Cairns
Professor of Health Economics, Public Health and Policy, London School of Hygiene and Tropical Medicine

Mr Matthew Campbell‑Hill
Lay member

Mr Mark Chapman
Health Economics and Market Access Manager, Medtronic UK

Dr Lisa Cooper
Echocardiographer, Stockport NHS Foundation Trust

Professor Daniel Hochhauser
Consultant in Medical Oncology, UCL Cancer Institute

Dr Neil Iosson
Locum General Practitioner

Mrs Anne Joshua
NHS 111 Pharmacy Lead, Patients and Information, NHS England

Dr Miriam McCarthy
Consultant, Public Health, Public Health Agency, Northern Ireland

Professor Ruairidh Milne
Professorial Fellow in Public Health, Wessex Institute, University of Southampton

Dr Peter Norrie
Principal Lecturer, De Montfort University, Leicester

Mr Chris O'Regan
Head of Health Technology & Outcomes Research, Merck Sharp & Dohme

Dr Sanjeev Patel
Consultant Physician and Senior Lecturer in Rheumatology, St Helier University Hospital

Dr John Pounsford
Consultant Physician, Frenchay Hospital, Bristol

Dr Danielle Preedy
Lay member

Mr Alun Roebuck
Consultant Nurse in Critical and Acute Care, United Lincolnshire NHS Trust

Mr Cliff Snelling
Lay member

Professor Ken Stein
Professor of Public Health, Peninsula College of Medicine and Dentistry, University of Exeter

Mr David Thomson
Lay member

Dr Nicky Welton
Senior Lecturer in Biostatistics and Health Technology Assessment, University of Bristol

Dr Nerys Woolacott
Senior Research Fellow, Centre for Health Economics, University of York

NICE project team

Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Caroline Hall
Technical Lead

Nicola Hay
Technical Adviser

Jeremy Powell
Project Manager

Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Companies were also invited to make written submissions. Professional or expert and patient or carer groups, and other consultees, had the opportunity to make written submissions. Companies, professional or expert and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Company:

Professional or expert and patient or carer groups:

Commentator organisations (did not provide written evidence and without the right of appeal):

The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on nintedanib by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the appraisal consultation document.

Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy. They were also invited to comment on the ACD.

ISBN: 978-1-4731-6168-9